Clinical Effect of Neoadjuvant Hierarchical Treatment Based on Chemotherapy

* Inclusion criteria * Pathologically confirmed to be rectal adenocarcinoma. * Distance \< 10cm from the end of the tumor to the anal verge found on colonoscopy * Tumor in stage T3-4N0-2 (pelvic MRI evaluation) * Patients without distant metastases (such as liver and peritoneum, lungs, aortic lymph nodes) * Patients with Karnofsky score greater ≥ 70 * WBC \> 3.5 x 109/ml , PLT \> 10 x 109/ml , TBIL\<22.2 umol/l , BUN \<7.14mmol/l , Cr\<132umol/l or Ccr \> 50ml/min (Evaluated using the Cockcroft-Gault formula: Creatinine clearance (male) = {(140 - age) x LBM (kg)} / {plasma creatinine (mg/dl) x 72} ; Creatinine clearance (female) = 0.85 x {(140 - age) x LBM(kg)}/ { plasma creatinine (mg/dl) x 72}) * Patients must sign the informed consent form * Female subjects must be contraceptive during the trial * Patients who did not receive any form of chemotherapy and radiotherapy * No other important related diseases (such as other tumors, severe heart disease and central nervous system diseases, etc.) * Age must be equal or more than 20 and must be equal or less than 70 * Exclusion criteria * Previously received radiation therapy, chemotherapy or anti-tumor biological therapy * Previously received immuno-suppressive therapy * Participation in interventional clinical trial over the past time * Suffering from malignant colonic neoplasms simultaneously * With peripheral neuropathy(above WHO I level) * Affected cognitive abilities because of neurological or psychiatric abnormalities Including central nervous system metastasis * Medical history of severe allergies or allergic constitution * Severe pulmonary or heart disease history * Female patients who are in pregnancy or lactation and refuse contraception * Previously with other malignant tumors * Exit criteria * Occurrence of bleeding, obstruction, perforation and other complications * Occurrence of distant metastasis during the period of neoadjuvant therapy * Adverse reactions, not be tolerated and do not want to continue to receive treatment * Patients voluntarily quit * Capecitabine-related Grade 4 Hand-Foot Syndrome